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Increasing evidence suggests that mesenchymal stem cells (MSCs) play anti-inflammatory roles during innate immune responses.
However, little is known about the effect of MSCs or their secretions on the ligand response of Toll-like receptor (TLR) 7 and TLR8,
receptors that recognize viral single-stranded RNA (ssRNA). Macrophages play a critical role in the innate immune response to
ssRNA virus infection; therefore, we investigated the effect of MSC-conditioned medium on cytokine expression in macrophages
following stimulationwithTLR7/8 ligands. After stimulationwithTLR7/8 ligand, bonemarrow-derivedmacrophages culturedwith
MSCs or in MSC-conditioned medium expressed lower levels of tumor necrosis factor (TNF) 𝛼 and interleukin (IL) 6 and higher
levels of IL-10 compared to macrophages cultured without MSCs or in control medium, respectively. The modulations of cytokine
expression were associated with prostaglandin E
2
(PGE
2
) secreted by the MSCs. PGE
2
enhanced extracellular signal-related kinase
(ERK) signaling and suppressed nuclear factor-𝜅B (NF-𝜅B) signaling. Enhanced ERK signaling contributed to enhanced IL-10
production, and suppression of NF-𝜅B signaling contributed to the low production of TNF-𝛼. Collectively, these results indicate
that MSCs and MSC-conditioned medium modulate the cytokine expression profile in macrophages following TLR7/8-mediated
stimulation, which suggests that MSCs play an immunomodulatory role during ssRNA virus infection.
1. Introduction
Several lines of evidence confirm that the adaptive immune
response plays a critical role in the effective control and clear-
ance of various kinds of viruses [1, 2]. In addition, recent stud-
ies have demonstrated that innate immune responses are also
important for viral clearance [3, 4]. Viral infection triggers
various innate immune receptors known as pattern recog-
nition receptors (PRRs), including Toll-like receptor (TLR),
Nod-like receptor (NLR), and RIG-I-like receptor (RLR) [5].
The TLR family of PRRs was the first to be identified and to
date is themost extensively studied. Both TLR7 and TLR8 are
located in endosomes; they recognize the genomes of single-
stranded RNA (ssRNA) viruses such as influenza virus and
human immunodeficiency virus (HIV). Recognition by these
receptors results in the activation of intracellular signaling
by nuclear factor-𝜅B (NF-𝜅B) and mitogen activated protein
kinases (MAPKs) through MyD88 activation, which in turn
leads to the production of proinflammatory cytokines and
chemokines and initiates various antiviral responses [5, 6].
In the lungs, macrophages as well as dendritic cells
(DCs) constitute the first line of innate host defenses against
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viral infection by contributing to the inhibition of viral
replication [4, 7]. For example, in influenza virus infection,
the highly pathogenic H5N1 avian influenza virus and the
H1N1 virus identified as the cause of the 2009 pandemic tend
to directly infect alveolar macrophages in addition to epithe-
lial cells [8]. Pharmacological depletion of macrophages
reportedly reduces the rate of survival in animal models of
influenza virus pneumonia, suggesting that macrophages are
essential for effective immune responses to influenza virus
infection [9]. During viral infection and associated TLR7/8
stimulation, macrophages produce various proinflammatory
cytokines such as TNF-𝛼 and IL-6, which leads to an
enhanced inflammatory response [10–12]. The production
of another major immunomodulatory cytokine, IL-10, is
also upregulated in TLR7/8-stimulatedmacrophages [12] and
ssRNA virus-infected macrophages [13].
Mesenchymal stem cells (MSCs) are multipotent mes-
enchymal stromal cells that can be isolated from various
tissues. They are capable of differentiating into mesodermal
lineage cells such as bone, cartilage, and fat cells [14]. A
growing body of evidence indicates that MSCs display
unique immunomodulatory properties during inflammation
in innate immune systems and that these cells are thus prom-
ising candidates for use in cell-mediated therapies for inflam-
matory diseases [15]. For example, MSC administration
protects against experimental sepsis in mice as a result of
enhanced production of the anti-inflammatory cytokine IL-
10 by macrophages in response to MSC-secreted prostaglan-
din E
2
(PGE
2
) [16]. Animal model studies have shown that
the protective actions of MSCs also occur in response to
acute lung injury induced by the TLR4 ligand lipopolysac-
charide (LPS) [17], chronic obstructive pulmonary disease
[18], pulmonary fibrosis [19], and bacterial pneumonia [20].
In addition, treatment withMSCs has been shown to improve
lung function in a human ex vivo-perfused TLR4-mediated
acute lung injury (ALI) model [21]. Although little is known
about the role that MSCs may play in the immune response
to viruses such as influenza viruses, the mechanism of MSC-
induced immunomodulation has been studied. Both cell-cell
contact and soluble factors secreted fromMSCs, such as PGE
2
[16], indoleamine 2,3 dioxygenase (IDO) [22], transforming
growth factor beta-1 (TGF-𝛽1) [23], hepatocyte growth factor
(HGF) [24], inducible nitric-oxide synthase (iNOS) [25], and
heme oxygenase-1 (HO1) [26], contribute to the modulation
of immune responses [14].
In the present study, we hypothesized that MSCs and
their soluble factors may modulate the cytokine expression
induced by the activation of TLR7/8-mediated signaling, a
major signaling pathway in innate immunity during ssRNA
virus infections. To investigate this hypothesis, we focused
on macrophages, which are critical components of the innate
immune response to viral infection. Here, we investigated
the effect of MSCs and MSC-conditioned medium on bone
marrow-derived macrophages (BMDMs) during TLR7/8
stimulation. We found that TLR7/8-mediated expression of
TNF-𝛼, IL-6, and IL-10 is modulated by enhancement of
extracellular signal-related kinase (ERK)-mediated signaling
and suppression of NF-𝜅B-mediated signaling in response to
PGE
2
secreted by MSCs.
2. Materials and Methods
2.1. Reagents. R848 (TLR7/8 ligand) and loxoribine (TLR7
ligand) were purchased from InvivoGen (San Diego, CA,
USA). The prostaglandin receptor EP2 antagonist AH6809
and EP4 antagonist GW 627368X were purchased from
Cayman (Ann Arbor, MI, USA). The MEK/ERK inhibitor
U0126, antibodies against the phosphorylated form of ERK,
p38, c-Jun N-terminal kinase (JNK), and total inhibitor of
kappa B (I𝜅B)-𝛼, as well as horseradish peroxidase-con-
jugated rabbit or mouse IgG secondary antibodies were pur-
chased fromCell Signaling Technology (Danvers,MA, USA).
Anti-𝛽-actin antibody was purchased from Sigma-Aldrich
(St. Louis, MO, USA).
2.2. Culture of Mesenchymal Stem Cells. Human MSCs were
obtained from Lonza (Allendale, NJ, USA), cultured in mes-
enchymal stem cell basal medium (MSCBM) supplemented
with MSCGM SingleQuots (Lonza), and subcultured every
3-4 days by using fresh media. The culture medium was
collected and centrifuged at 600×g for 10min. The super-
natant was used in further experiments as MSC-conditioned
medium, while cell-free medium incubated under the same
conditions as the MSC-conditioned medium served as a
control. All media were kept at −80∘C until use.
2.3. Culture of Murine Bone Marrow-Derived Macrophages.
Bone marrow cells were harvested from 8- to 10-week-old
male C57/B6 mice (Charles River Laboratories Japan, Inc.,
Yokohama, Japan) by flushing the femur and tibia with
RPMI 1640 medium. Recovered cells were then cultured in
bone marrow cell medium (20% FCS, 30% L-cell super-
natant, 2mM l-glutamine, 1% penicillin/streptomycin, and
0.25 𝜇g/mL amphotericin B in RPMI 1640). Fresh bone mar-
row cell medium was added on day 3. On day 6, the adherent
cells were replated in RPMI 1640medium supplemented with
10% FCS, 2mM l-glutamine, and 1% penicillin/streptomycin
for use as BMDMs. On day 7, the medium was removed and
replaced with either MSC-conditioned medium, or control
medium and the cells were incubated for 1 h, after which they
were stimulated with either R848 or loxoribine.
2.4. Enzyme-Linked Immunosorbent Assay. Levels of TNF-
𝛼, IL-6, GM-CSF, IL-12 p70, and IL-10 were determined
using a DuoSet ELISA Kit (R&D Systems, Minneapolis, MN,
USA), and PGE
2
levels were measured using an ELISA kit
(Cayman), according to the manufacturer’s instructions.
2.5. Quantitative Real-Time PCR. Total RNA was isolated
using RNeasy Mini kits (QIAGEN, Valencia, CA, USA)
and reverse transcribed using High Capacity cDNA Reverse
Transcription kits (Applied Biosystems, Foster City, CA,
USA), according to the manufacturers’ instructions. Quanti-
tative real-time PCR (qRT-PCR) analysis with SYBR Green
was performed on a 7500 Fast Real-Time PCR System
(Applied Biosystems). The sequences of the primers were
as follows: 5󸀠-GGTCAAAGGTTTGGAAGCAG-3󸀠 (for-
ward) and 5󸀠-TGTGAAATGCCACCTTTTGA-3󸀠 (reverse)
for Il1b; 5󸀠-TCTCCGTTACTTGGGGACAC-3󸀠 (forward)
and 5󸀠-CCACACTCAAGAATGGTCGC-3󸀠 (reverse) for
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Cxcl1; 5󸀠-GTGGAATCTTCCGGCTGTAG-3󸀠 (forward) and
5󸀠-ACCATGACACTCTGCAACCA-3󸀠 (reverse) for Ccl3;
5󸀠-CCACTTCTTCTCTGGGTTGG-3󸀠 (forward) and 5󸀠-
GTGCCCACGTCAAGGAGTAT-3󸀠 (reverse) for Ccl5; and
5󸀠-TTGATGGCAACAATCTCCAC-3󸀠 (forward) and 5󸀠-
CGTCCCGTAGACAAAATGGT-3󸀠 (reverse) for Gapdh,
which was used as a loading control.
2.6. Immunoblotting. Following R848 stimulation, BMDMs
were lysed in RIPA buffer (Thermo Fisher Scientific,
Waltham, MA, USA) supplemented with protease inhibitor
cocktail (Sigma-Aldrich) and phosphatase inhibitor (Thermo
Fisher Scientific) at various time points. Lysed BMDMs were
kept on ice for 30min and then centrifuged at 15,000×g for
15min. The supernatant was collected and stored at −80∘C
until use. The total protein concentration of each sample
was determined using the bicinchoninic acid protein assay
(Thermo Fisher Scientific). Equal amounts (10–30 𝜇g) of cell
lysate were separated by SDS-PAGE (Bio-Rad, Hercules, CA,
USA), and the proteins were then transferred onto polyvinyl
difluoride membranes (Invitrogen, Carlsbad, CA, USA).
After overnight incubation with each primary antibody, the
membrane was washed, stained with horseradish peroxidase-
conjugated rabbit or mouse IgG secondary antibody, and
visualized using enhanced chemiluminescence detection
reagents (ECL; GE Healthcare, Piscataway, NJ, USA). The
images were analyzed using ImageJ 1.37v (National Institutes
of Health, Bethesda, MD, USA).
2.7. RelA Transfection Study. BMDMs were transfected with
the RelA cFlag pcDNA3 plasmid (gift fromProfessor Stephen
Smale) or pcDNA3.1 plasmid (gift from Professor Stephen
Smale) using the FuGENE6 Transfection Reagent (Promega,
Madison,WI, USA), according to themanufacturer’s instruc-
tions. At 24 h after transfection, the cells were cultured for 1 h
in eitherMSC-conditionedmedium or controlmedium, after
which they were incubated with either TLR7/8 ligand (R848)
or vehicle, without changing the medium.
2.8. Statistical Analysis. Data are expressed as the mean ±
SEM. Differences were analyzed for statistical significance
using an unpaired 𝑡-test or ANOVA, followed by Tukey’s
test for multiple comparisons. 𝑃 values less than 0.05 were
considered statistically significant.
3. Results
3.1.MSCsModulate Cytokine Levels after TLR7/8 Ligand Stim-
ulation. To investigate the effect of MSCs on cytokine pro-
duction by BMDMs following TLR7/8 ligand stimulation,
we cocultured MSCs and BMDMs and examined cytokine
production following stimulation with either the TLR7/8
(R848) or TLR7 (loxoribine) ligand. MSCs inhibited the pro-
duction of TNF-𝛼, IL-6, and GM-CSF by BMDMs after
R848 and loxoribine stimulation. The level of IL-12 p70 was
lower in cocultured BMDMs after R848 stimulation, but not
after loxoribine stimulation. The level of IL-10 was higher
in cocultured BMDMs after R848 stimulation, but not after
loxoribine stimulation (Figure 1).
3.2. MSC-Conditioned Medium Modulates Cytokine Levels
after TLR7/8 Ligand Stimulation. Next, we examined wheth-
er MSCs produce soluble factors that modulate cytokine
production by macrophages stimulated with TLR7/8 ligands.
BMDMs were preincubated in either MSC-conditioned or
control medium and then stimulated with the TLR7/8 (R848)
or TLR7 (loxoribine) ligand. The production of TNF-𝛼,
IL-6, and GM-CSF following R848 or loxoribine stimula-
tion was significantly lower in BMDMs preincubated in
MSC-conditioned medium than in BMDMs preincubated
in control medium (Figures 2(a)–2(c)). IL-12 p70 was not
detected in either case (Figure 2(d)). In contrast, R848-
and loxoribine-stimulated BMDMs preincubated in MSC-
conditioned medium produced higher levels of IL-10 than
did R848- and loxoribine-stimulated BMDMs preincubated
in control medium (Figure 2(e)). These results indicate that
MSCs secrete factors that suppress the production of TNF-𝛼,
IL-6, and GM-CSF and enhance the production of IL-10 by
TLR7/8 ligand-stimulated BMDMs.
We also examined the expression of other virus-related
cytokines. The production of mRNA encoding Il1b, CXC
ligand (Cxcl)1, CC ligand (Ccl)3, and Ccl5 was suppressed in
both R848- and loxoribine-stimulated BMDMs preincubated
in MSC-conditioned medium (Figures 2(f)–2(i)).
3.3. PGE
2
/PGE
2
Receptors Contribute to the Modulation of
Cytokine Production in MSC-Conditioned Medium. PGE
2
is
a major immunomodulator secreted by MSCs [14], and a
previous study demonstrated that PGE
2
secreted fromMSCs
contributes to enhanced IL-10 production by macrophages
[16]. Therefore, we examined whether PGE
2
contributes to
the immunomodulatory effect of MSC-conditioned medium
on TLR7/8 ligand (R848)-stimulated BMDMs. We first con-
firmed that PGE
2
was present in MSC-conditioned medium,
but not in control medium (Figure 3(a)). We then measured
the level of PGE
2
in the supernatant of BMDMs before and
after TLR7/8 ligand (R848) stimulation. The level was below
the detection limit, suggesting that PGE
2
is not secreted by
macrophages after TLR7/8 ligand stimulation (data not
shown).
Next, BMDMs were preincubated for 1 h with the pros-
taglandin E2 receptor EP2 or EP4 antagonist in MSC-condi-
tioned or control medium, after which the cells were stim-
ulated with R848. The results are shown in Figures 3(b)–
3(d).The level of TNF-𝛼 produced by cells preincubated with
the EP2 or EP4 receptor antagonist was significantly higher
than that produced by cells stimulated with R848 alone (Fig-
ure 3(b)).The level of IL-6 increased significantly in BMDMs
preincubated with the EP4 antagonist in MSC-conditioned
medium, but not in cells preincubated with the EP2 antago-
nist (Figure 3(c)). In addition, the observed enhancement in
IL-10 production was partly abrogated by the EP4 antagonist,
but not by the EP2 antagonist (Figure 3(d)). These results
indicate that the observed decreases in the expression of
TNF-𝛼 and IL-6 and the observed increase in the expression
of IL-10 were due, at least in part, to PGE
2
secreted by MSCs.
3.4. MSC-Conditioned Medium Enhances ERK Signaling and
Suppresses NF-𝜅B Signaling in TLR7/8 Ligand-Stimulated
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Figure 1: Modulation of cytokine expression by BMDMs cocultured with MSCs and then stimulated with TLR7/8 ligands. BMDMs (0.4 ×
106 cells/well) were incubated with or without MSCs (0.4 × 106 cells/well) in 24-well plates. After 1 h, the cells were incubated with R848
(TLR7/8 ligand, 10 𝜇g/mL) or loxoribine (TLR7 ligand, 300 𝜇g/mL) for 24 h. The levels of murine TNF-𝛼, IL-6, GM-CSF, IL-12 p70, and IL-
10 in the culture supernatant were determined using ELISA. Data are expressed as the mean ± SEM. 𝑛 = 3 in each group. ∗𝑃 < 0.05 and
∗∗
𝑃 < 0.01, compared to the control group. N.D., not detected. Results are representative of 3 independent experiments.
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Figure 2: Modulation of cytokine expression by BMDMs incubated in MSC-conditioned medium and then stimulated with TLR7/8 ligands.
BMDMswere preincubated for 1 h inMSC-conditionedmediumor controlmedium and then incubatedwith R848 (TLR7/8 ligand, 10 𝜇g/mL)
or loxoribine (TLR7 ligand, 300 𝜇g/mL) for 24 h. (a–e) The levels of murine TNF-𝛼 (a), IL-6 (b), GM-CSF (c), IL-12 p70 (d), and IL-10 (e) in
the culture supernatant were determined using ELISA. Data are expressed as themean ± SEM. 𝑛 = 3 in each group. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01,
compared to the control medium group. N.D., not detected. (f–i)The levels of Il1b (f),Cxcl1 (g),Ccl3 (h), andCcl5 (i) mRNAwere determined
using qRT-PCR. Data are expressed as fold increase over the level in the control medium group without TLR7/8 ligand stimulation (mean ±
SEM). 𝑛 = 3 in each group. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01, compared to the control medium group. Results are representative of 3-4 independent
experiments.
BMDMs. Because MSC-conditioned medium modulated
cytokine expression, especially after R848 stimulation, we
examined the effect of MSC-conditioned medium on sig-
naling mediated by the MAPK and NF-𝜅B pathways, both
of which play important roles in TLR-mediated cytokine
expression [27]. The level of phosphorylated (p)-ERK was
elevated 0.5 h after R848 stimulation in BMDMs preincu-
bated in MSC-conditioned medium compared to the level
in cells preincubated in control medium (Figures 4(a) and
4(b)). At 1 h after R848 stimulation, the level of total I𝜅B-𝛼,
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Figure 3: Contribution of PGE
2
/EP to the modulation of cytokine expression in BMDMs incubated in MSC-conditioned medium and then
subjected to R848 stimulation. (a) PGE2 levels inMSC-conditionedmedium or control mediumweremeasured by ELISA. N.D., not detected.
(b–d) BMDMs were incubated in MSC-conditioned medium or control medium with EP2 antagonist (AH6809, 10 𝜇M) or EP4 antagonist
(GW 627368X, 10𝜇M). DMSO was used as the vehicle for each EP antagonist. After 1 h, R848 (TLR7/8 ligand, 10 𝜇g/mL) was added, and the
BMDMs were incubated for an additional 24 h. The levels of TNF-𝛼 (b), IL-6 (c), and IL-10 (d) were determined using ELISA. ∗𝑃 < 0.05,
compared to the control medium group. #𝑃 < 0.05, compared to the R848-stimulated cells (without EP antagonist). Data are expressed as the
mean ± SEM. 𝑛 = 3 in each group. Results are representative of 3 independent experiments.
the inhibitory protein ofNF-𝜅B,was higher inBMDMsprein-
cubated in MSC-conditioned medium than in cells prein-
cubated in control medium (Figures 4(c) and 4(d)). These
results indicate thatMSC-conditionedmedium enhances sig-
naling mediated by ERK and suppresses signaling mediated
by NF-𝜅B in BMDMs stimulated with R848.
3.5. Involvement of ERK Signaling in Modulation of IL-10
Expression in BMDMs Preincubated inMSC-ConditionedMe-
dium. To determine whether the PGE
2
present in MSC-con-
ditioned medium is responsible for the observed enhance-
ment of ERK signaling in R848-stimulated BMDMs, we
measured the level of p-ERK after R848 stimulation in
BMDMs cultured in MSC-conditioned medium or control
medium with or without a cocktail composed of the EP2
and EP4 antagonists. Treatment with the EP2/EP4 antago-
nist cocktail abrogated the increase in the level of p-ERK
in R848-stimulated BMDMs cultured in MSC-conditioned
medium (Figure 5(a)), suggesting that PGE
2
/EP plays a role
in increasing the level of p-ERK in BMDMs incubated in
MSC-conditioned medium.
We then examined whether enhanced p-ERK expression
contributes to the observed suppression of TNF-𝛼 and IL-6
expression and enhancement of IL-10 expression in BMDMs
incubated in MSC-conditioned medium. For this experi-
ment, BMDMs were preincubated in MSC-conditioned or
control medium containing the MEK/ERK inhibitor U0126
or dimethyl sulfoxide (DMSO, as a vehicle control), after
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Figure 4: Enhanced ERK and suppressed NF-𝜅B signaling in BMDMs incubated in MSC-conditioned medium and then subjected to R848
stimulation. BMDMs were preincubated for 1 h in MSC-conditioned medium or control medium, after which R848 (TLR7/8 ligand,
10𝜇g/mL) was added. Cells were further incubated for the indicated times. (a) The levels of p-p38, p-JNK, and p-ERK were determined by
immunoblotting. Beta-actin was used as a loading control. Relative band intensities ware quantified by densitometry analysis. (b)The data of
(a) at 0.5 h after R848 stimulation obtained by densitometric analysis are shown as the mean ± SEM of 3 independent experiments. (c) The
level of total I𝜅B-𝛼 was determined by immunoblotting. Beta-actin was used as a loading control. Relative band intensities ware quantified
by densitometry analysis. (d) The data of (c) at 1 h after R848 stimulation obtained by densitometric analysis are shown as the mean ± SEM
of 3 independent experiments. ∗𝑃 < 0.05, compared to the control medium group.
which the cells were stimulated with R848. In cells incubated
in the control medium, addition of U0126 resulted in a
decrease in the levels of TNF-𝛼, IL-6, and IL-10 after R848
stimulation (Figures 5(b)–5(d)), suggesting that MEK/ERK
activation is essential for the production of these cytokines
in R848-stimulated BMDMs. As shown previously in Fig-
ure 2(a), we confirmed that incubation in MSC-conditioned
medium results in a significant decrease in the levels of
TNF-𝛼 and IL-6 and a significant increase in the level of
IL-10 after R848 stimulation (Figures 5(b)–5(d)). In cells
incubated in MSC-conditioned medium, addition of U0126
did not increase the production of TNF-𝛼 and IL-6 after R848
stimulation (Figures 5(b) and 5(c)), suggesting that the stim-
ulation of p-ERK expression induced by MSC-conditioned
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Figure 5: ERK signaling is partially responsible for themodulated expression of IL-10, but not that of TNF-𝛼 or IL-6, in BMDMs preincubated
inMSC-conditionedmedium followed byR848 stimulation. (a) BMDMswere preincubated inMSC-conditionedmediumor controlmedium
with or without a cocktail consisting of an EP2 antagonist (AH6809, 10𝜇M) and an EP4 antagonist (GW 627368X, 10𝜇M). DMSO was used
as a vehicle. After 1 h, R848 (TLR7/8 ligand, 10 𝜇g/mL) was added, and BMDMs were incubated for an additional 0.5 h. The p-ERK level was
determined by immunoblotting. Beta-actin was used as a loading control. Results are representative of 3 independent experiments. (b–d)
BMDMs were preincubated in MSC-conditioned medium or control medium with or without MEK/ERK inhibitor (U-0126, 10 𝜇M). DMSO
was used as the vehicle. After 1 h, R848 (TLR7/8 ligand, 10 𝜇g/mL) was added, and BMDMs were incubated for an additional 24 h. The levels
of TNF-𝛼 (a), IL-6 (c), and IL-10 (d) were determined using ELISA. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01, compared to the control medium group.
#
𝑃 < 0.05, compared to the R848-stimulated cells (withoutMEK/ERK inhibitor). Data are expressed as the mean ± SEM. 𝑛 = 3 in each group.
Results are representative of 3 independent experiments.
medium does not contribute to the decreased expression
of TNF-𝛼 or IL-6. On the other hand, treatment with U0126
resulted in a significant decrease in IL-10 production in R848-
stimulated BMDMs incubated inMSC-conditionedmedium.
The IL-10 level in these cells was comparable to that in
R848-stimulated/U0126-treated BMDMs cultured in control
medium (Figure 5(d)). These results suggest that enhanced
p-ERK expression contributes at least partially to the
enhancement of IL-10 production in BMDMs cultured in
MSC-conditioned medium.
3.6. Involvement of NF-𝜅B Signaling in Modulation of TNF-𝛼
Expression in BMDMs Incubated in MSC-Conditioned Medi-
um. To determine whether the suppression of NF-𝜅B signal-
ing observed inR848-stimulated BMDMs incubated inMSC-
conditioned medium is PGE
2
-dependent, we measured the
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Figure 6: NF-𝜅B signaling is partially responsible for the modulated expression of TNF-𝛼, but not that of IL-6 or IL-10, in BMDMs
preincubated in MSC-conditioned medium and then subjected to R848 stimulation. (a) BMDMs were incubated in MSC-conditioned
medium or control medium with or without a cocktail consisting of an EP2 antagonist (AH6809, 10 𝜇M) and EP4 antagonist (GW 627368X,
10𝜇M). DMSO was used as the vehicle. After 1 h, R848 (TLR7/8 ligand, 10 𝜇g/mL) was added, and BMDMs were incubated for an additional
1 h. The level of total I𝜅B-𝛼 was determined by immunoblotting. Beta-actin was used as a loading control. Results are representative of 3
independent experiments. (b–e) BMDMs were transfected with RelA cFlag pcDNA3 plasmid or pcDNA3.1 plasmid (as a control) using
FuGENE6 Transfection Reagent. After 24 h, the cells were incubated for 1 h in either MSC-conditioned medium or control medium, after
which they were stimulated with TLR7/8 ligand (R848) or vehicle for 24 h in either MSC-conditioned medium or control medium.The level
ofRelamRNAwas determined using qRT-PCR (b). Data are expressed as the fold increase over the level ofRela in control plasmid-transfected
cells cultured in control medium without R848 stimulation (mean ± SEM). #𝑃 < 0.05, compared to the control plasmid-transfected cells.The
levels of TNF-𝛼 (c), IL-6 (d), and IL-10 (e) in the supernatant were determined using ELISA. ∗𝑃 < 0.05, compared to the control medium
group. #𝑃 < 0.05, compared to the control plasmid-transfected cells. Data are expressed as the mean ± SEM. 𝑛 = 3 in each group. Results are
representative of 3 independent experiments.
total I𝜅B-𝛼 level in BMDMs cultured in MSC-conditioned
or control medium with or without a cocktail composed of
the EP2 and EP4 antagonists. The level of total I𝜅B-𝛼 was
significantly lower in BMDMs cultured in MSC-conditioned
medium containing the EP2/EP4 antagonist cocktail than
in cells cultured in MSC-conditioned medium without the
antagonist cocktail, suggesting that PGE
2
/EP plays a role in
the inhibition of total I𝜅B-𝛼 degradation (i.e., suppression
of NF-𝜅B signaling) in cells cultured in MSC-conditioned
medium (Figure 6(a)).
We also investigated whether suppression of NF-𝜅B sig-
naling contributes to the suppression of TNF-𝛼 and IL-
6 expression and enhancement of IL-10 expression by
transfecting BMDMs with either the RelA cFlag pcDNA3
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plasmid or a control c-Flag pcDNA3 plasmid. Trans-
fected cells were then incubated in either MSC-conditioned
medium or control medium and stimulated with R848.As
shown in Figure 6(b), Rela mRNA production was strongly
induced in cells transfected with the RelA cFlag pcDNA3
plasmid. In cells incubated in the control medium, RelA
overexpression resulted in no significant increase in the levels
of TNF-𝛼, IL-6, or IL-10 after R848 stimulation (Figures
6(c)–6(e)). In contrast, RelA overexpression enhanced the
expression of TNF-𝛼 (but not IL-6 or IL-10) in cells incubated
in MSC-conditioned medium (Figures 6(c)–6(e)). The pro-
duction of TNF-𝛼 in RelA-transfected cells cultured inMSC-
conditioned medium and control medium was comparable
(Figure 6(c)). These results indicate that the expression of
TNF-𝛼 in BMDMs incubated in MSC-conditioned medium
is mediated at least in part by NF-𝜅B signaling.
4. Discussion
In this study, we investigated the effects of MSCs and MSC-
conditioned medium on macrophages during TLR7/8-medi-
ated immune responses and demonstrated the following
salient findings: (1) TLR7/8-mediated cytokine expression,
including that of TNF-𝛼, IL-6, and IL-10, in macrophages
is modulated by coincubation with MSCs; (2) soluble fac-
tors secreted by MSCs modulate TLR7/8-mediated cytokine
expression in macrophages; (3) PGE
2
secreted by MSCs is
involved in this modulation; (4) ERK signaling is enhanced
and NF-𝜅B signaling is suppressed after TLR7/8 ligand stim-
ulation when macrophages are cultured in MSC-conditioned
medium, and these effects are primarily due to PGE
2
; (5)
ERK signaling is involved in enhanced IL-10 production in
macrophages cultured inMSC-conditionedmedium; and (6)
NF-𝜅B signaling is involved in suppressed TNF-𝛼 (but not
IL-6) expression in macrophages cultured in MSC-condi-
tioned medium.
A growing body of evidence indicates that MSCs have
immunomodulatory roles in innate immune responses;
therefore, MSC-based therapies are increasingly viewed as
promising means of treating various inflammatory diseases,
such as sepsis [16], acute lung injury [17], and bacterial pneu-
monia [20]. In the present study, we hypothesized that MSCs
maymodulate TLR7/8-mediated signaling, a major signaling
pathway activated by infection with ssRNA viruses such as
influenza virus and HIV.
Macrophages are one of themost important cellular com-
ponents of the inflammatory and innate immune responses
that occur in the lung following infection with microorgan-
isms such as bacteria and viruses [4, 28]. Recent reports indi-
cate thatmacrophages play a pivotal role in the immunomod-
ulation of MSCs during TLR4 (LPS)-mediated innate
immune responses [17, 20]; however, the effect of MSCs on
innate immune responses to ligands for TLR7/8, the receptors
that recognize viral single-strandedRNA, is largely unknown.
Therefore, we focused our investigation on the effect ofMSCs
on TLR7/8-mediated cytokine expression in macrophages.
Our results indicate that TLR7/8-mediated induction of
proinflammatory cytokine expression (e.g., TNF-𝛼 and IL-
6) was suppressed in BMDMs cultured in MSC-conditioned
medium, suggesting that MSC-conditioned medium played
an anti-inflammatory role in the present study. The sig-
nificance of the induction of TNF-𝛼 and IL-6 expression
following the TLR7/8-mediated response to ssRNA virus
infection is not fully known. Infection with influenza virus,
a major ssRNA virus, induces a significant increase in the
production of TNF-𝛼 and IL-6 by macrophages, leading
to enhanced inflammatory responses [11, 29]. In addition,
increased TNF-𝛼 and IL-6 production can potentiate the
severity of combined influenza A virus and bacterial infec-
tions [30, 31]. Another study demonstrated that the level of
IL-6 expression correlates with disease severity in pediatric
H1N1 infection [32]. Based upon these data, we speculate
that the suppression of TLR7/8-mediated TNF-𝛼 and IL-
6 expression by MSC-conditioned medium modulates the
pathogenesis of ssRNA virus infection, including infection by
influenza virus.
The expression of IL-10 was highly upregulated in
BMDMs after TLR7/8 ligand stimulation in the present study,
consistent with previous reports demonstrating that IL-10
expression is highly upregulated in macrophages following
TLR7/8 ligand stimulation [33] and influenza virus infection
[13]. Interestingly, we found that culturing BMDMs in MSC-
conditionedmedium increased the level of IL-10 after TLR7/8
ligand stimulation. The significance of TLR7/8-mediated
induction of IL-10 expression in macrophages is contro-
versial. However, given that IL-10 suppresses the induction
of TNF-𝛼 and IL-6 expression in TLR ligand-stimulated
macrophages [34], it is possible that IL-10 also inhibits the
induction of TNF-𝛼 and IL-6 expression by macrophages,
leading to the suppression of inflammatory responses
observed in the present study.
In the presence of loxoribine (TLR7 ligand), IL-10 levels
were comparable in BMDMs cultured alone and in BMDMs
cocultured with MSCs. However, in the presence of lox-
oribine, the IL-10 level was higher in BMDMs cultured in
MSC-conditioned medium than in cells cultured in control
medium. A possible reason for the discrepancy is the effect
of cell-cell contact between BMDMs and MSCs, which may
modulate cell surfacemarkers, change intracellular signaling,
and modulate loxoribine-induced IL-10 production in the
present study.
The mechanism of MSC-mediated immunomodulation
has been investigated. Soluble factors produced by MSCs as
well as cell-cell contact are thought to be important for the
immunomodulatory effects [14]. Various immunosuppres-
sive factors secreted by MSCs mediate the immunomodu-
latory effects, including PGE
2
[16], IDO [22], TGF-𝛽1 [23],
HGF [24], iNOS [25], and HO1 [26]. Among these factors,
we focused on the role of PGE
2
because PGE
2
, is a major
secretory product of MSCs, and it can modulate cytokine
expression, especially in macrophages [16].
Prostaglandin E
2
is a major metabolite of arachidonic
acid. It regulates inflammation and multiple functions of
immune cells [35, 36]. Four PGE
2
receptors have been iden-
tified: EP1, EP2, EP3, and EP4. The cAMP/PKA/CREB sig-
naling pathway is activated through EP2 and EP4, both of
which are responsible for the anti-inflammatory function
of PGE
2
[36]. The results of the present study indicate
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that the PGE
2
-EP2 and PGE
2
-EP4 pathways play important
roles in the modulation of cytokine expression. The role
of PGE
2
in TNR7/8-mediated responses, including ssRNA
virus infection, is not fully known; however, recent reports
suggest that PGE
2
protects against ssRNA virus infection in
vitro [37, 38]. These results led us to speculate that PGE
2
secreted by MSCs following ssRNA virus infection may play
an immunoregulatory role in vivo by modulating cytokine
expression. MSC-based therapy against ssRNA virus infec-
tion may be useful for patients with severe viral infection,
such as those infected by the pandemic influenza 2009
H1N1 virus. In these cases, a cytokine storm can be lethal
[39], and MSC-mediated suppression of proinflammatory
cytokines (e.g., TNF-𝛼 and IL-6) protects against severe
influenza virus infection. In vivo animal studies and clinical
trial are required to fully understand the in vivo roles of
MSCs.
Activation of TLR7/8 signaling throughMyD88 results in
the activation of MAPKs and the NF-𝜅B signaling pathway,
leading to the expression of various cytokines [13]. Previ-
ous studies have demonstrated that PGE
2
inhibits NF-𝜅B-
mediated transcription [40, 41]. In addition, PGE
2
reportedly
enhances signaling via the ERK pathway [42]. Therefore, we
examined the expression of signaling molecules associated
with the MAPK and NF-𝜅B pathways. Interestingly, the
expression of p-ERK, an activated form of ERK, was higher
and the expression of total I𝜅B-𝛼, an inhibitory protein of
NF-𝜅B, was lower in BMDMs cultured in MSC-conditioned
medium than in cells cultured in control medium, indicating
that ERK signaling was activated and NF-𝜅B signaling was
suppressed by the MSC-conditioned medium. In the present
study, the EP2/EP4 antagonist cocktail decreased the level of
p-ERK and total-I𝜅B-𝛼, confirming that PGE
2
contributes
to enhanced ERK and suppressed NF-𝜅B signaling. We
found that suppressed NF-𝜅B signaling was associated with
suppressed TNF-𝛼 expression. We also found that enhanced
ERK signaling was associated with enhanced IL-10 expres-
sion, consistent with a previous report indicating that ERK
signaling is one of the primary pathways leading to IL-10
production in macrophages [43].
Macrophages can be phenotypically polarized into 2main
groups depending on the microenvironment: M1 (classical)
or M2 (alternative) activated macrophages. TNF-𝛼 and IL-6,
proinflammatory cytokines, are M1 macrophage markers,
and IL-10 is an M2 macrophage marker [44]. Therefore, our
results indicate that MSC or MSC-conditioned medium can
polarize macrophage population toward an M2 phenotype.
Other M1/M2 markers were not measured. A recent report
indicates that MSCs and MSC-conditioned medium pro-
tect against LPS-induced acute lung injury by polariz-
ing the macrophage population toward an M2 phenotype
[45].
We used human-derived MSCs in the present study.
These cells were used because results obtained using human
MSCs may be more relevant to clinical settings and because
little is known about the behavior of human MSCs during
inflammatory responses, although the beneficial effects of
human MSCs have been reported in studies of a mouse
model of Gram-negative sepsis [46], LPS-induced ALI [47],
and Escherichia coli pneumonia [48]. Suppression of TNF-𝛼
and IL-6 expression and enhancement of IL-10 expression
were observed in the present study when R848-stimulated
BMDMswere cultured inmurineMSC-conditionedmedium
(data not shown), confirming that these immunomodulatory
effects were not specific to human MSCs.
There are several limitations to the present study. First, the
pathway responsible for the suppression of IL-6 expression
in cells incubated in MSC-conditioned medium is unknown.
Neither the ERK nor NF-𝜅B signaling pathways were respon-
sible for the suppression of IL-6 expression.The Janus kinase/
signal transducer and activator of transcription/suppressor of
cytokine signaling and phosphoinositol-3-kinase pathways,
both of which are important for IL-6 production [49, 50],
could be responsible. Second, MSCs secrete soluble factors
aside from PGE
2
that can modulate TLR7/8-mediated sig-
naling, such as TGF-𝛽 [23], which has been shown to sup-
press the production of proinflammatory cytokines in
macrophages [51]. Further studies are required in order to
obtain a complete understanding of the modulatory roles of
MSCs.
In summary, we have demonstrated that MSC-condi-
tioned medium has an immunomodulatory effect on macro-
phages. In macrophages incubated in MSC-conditioned
medium, TLR7/8-mediated expression of the proinflamma-
tory cytokines TNF-𝛼 and IL-6 was suppressed, and the
expression of IL-10 was enhanced. These effects were medi-
ated, in part, by PGE
2
. Suppression of NF-𝜅B signaling con-
tributed to the suppression of TNF-𝛼 expression, and activa-
tion of ERK signaling contributed to enhanced IL-10 expres-
sion. These results indicate that MSC-conditioned medium
modulates the cytokine expression profile of cells stimulated
with TLR7/8. Our results also suggest that MSCs may play
anti-inflammatory roles by modulating cytokine expression
during infection by ssRNA viruses, such as influenza virus.
Thus, MSCs are a potential therapeutic target for treating
ssRNA virus infections.
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